Oxycodone
- Generic Name
- Oxycodone
- Brand Names
- Endocet, Endodan Reformulated May 2009, Nalocet, Oxaydo, Oxy.IR, Oxycontin, Oxyneo, Percocet, Prolate, Rivacocet, Roxicet, Roxicodone, Roxybond, Targin, Targiniq, Xolox, Xtampza
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21NO4
- CAS Number
- 76-42-6
- Unique Ingredient Identifier
- CD35PMG570
- Background
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period. The first oxycodone containing product, Percodan, wa...
- Indication
Oxycodone is indicated for the treatment of moderate to severe pain. There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.
- Associated Conditions
- Severe Acute Pain, Severe Pain, Severe, Chronic Pain, Acute, moderate Pain, Chronic, moderate Pain
- Associated Therapies
- -
Abuse Potential Study of PF-00345439
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Pain Therapeutics
- Target Recruit Count
- 67
- Registration Number
- NCT01986283
- Locations
- 🇺🇸
Lifetree Clinical Research, Salt Lake City, Utah, United States
Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- VistaPharm, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT01959204
- Locations
- 🇺🇸
Miami Children's Hospital, Miami, Florida, United States
🇺🇸Tampa General Hospital, Tampa, Florida, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2016-04-14
- Target Recruit Count
- 150
- Registration Number
- NCT01946555
- Locations
- 🇮🇹
A.O. Universitaria Parma, Parma, Italia, Italy
🇮🇹Ospedale di Piacenza, Piacenza, Italy
🇮🇹Ospedale Magati, Scandiano, Italia, Italy
Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Pain Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT01924676
- Locations
- 🇺🇸
Pfizer Investigational Site, Baltimore, Maryland, United States
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
- Target Recruit Count
- 232
- Registration Number
- NCT01885182
- Locations
- 🇨🇳
The sixth hospital of shanghai, Shanghai, China
🇨🇳Tianjin Cancer Hospital, Tianjin, China
🇨🇳Beijing Friendship Hospital, Beijing, China
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
- Conditions
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- BioDelivery Sciences International
- Target Recruit Count
- 39
- Registration Number
- NCT01871285
- Locations
- 🇺🇸
CRI Lifetree (Lifetree Clinical Research), Salt Lake, Utah, United States
🇺🇸CRI Lifetree, Philadelphia, Pennsylvania, United States
🇺🇸Vince and Associates Clinical Research, Inc., Overland Park, Kansas, United States
Emergency Department (ED) Drug Interaction in Emergency Department Patients
- Conditions
- Interventions
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 502
- Registration Number
- NCT01859715
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users
- Conditions
- Interventions
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 89
- Registration Number
- NCT01825447
- Locations
- 🇺🇸
Pfizer Investigational Site, Salt Lake City, Utah, United States
RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.
- Conditions
- Interventions
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2015-12-24
- Target Recruit Count
- 518
- Registration Number
- NCT01809106
- Locations
- 🇮🇹
Multimedica, Sesto San Giovanni, Italy
🇮🇹Istituto Scientifico San Raffaele, Milano, Italy
🇮🇹Arcispedale S. Maria Nuova Azienda Ospedaliera, Reggio Emilia, RE, Italy
Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Pain Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT01717027
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.